Uncategorized
Advertisement
Lucence will provide access to LiquidHALLMARK, a next-generation sequencing liquid biopsy, through Mayo Clinic Laboratories.
Compared with placebo, tranexamic acid did not reduce bleeding in patients undergoing intensive chemotherapy.
Real-world data and clinical trial data may support less TLS monitoring in patients with CLL who receive venetoclax.
The functional and structural relevance of IGHV1-204 remains unclear for patients with splenic marginal zone lymphoma.
cookie test
In the last segment of the roundtable series, the panel discusses the future of myelofibrosis treatment.
Advertisement
The panel discusses the four JAK inhibitors approved by the FDA: ruxolitinib, fedratinib, pacritinib, and momelotinib.
In the sixth segment of the roundtable series, the panel discusses momelotinib and pacritinib treatment in myelofibrosis.
The panel discusses fedratinib for myelofibrosis and whether it's used in the frontline or second line setting.
In the fourth segment of the roundtable series, the panel discusses frontline ruxolitinib treatment for myelofibrosis.
This roundtable session addresses which patients go directly to transplant, when to observe patients, and more.
In the first segment of the roundtable series, the panel discusses how myelofibrosis is diagnosed and assessed.
Dr. Naveen Pemmaraju discusses the history of prognostic scoring systems and how they factor into frontline therapy planning.
“I’m grateful to shed a spotlight on hematopathology and what we contribute to these patients," Dr. Loghavi said.
Dr. Zeidan will be participating in the myelodysplastic syndromes panel on the second day of the event
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.